Clinical trial

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

NCT03960541

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-08-31

PhasePHASE2

Study timeline

Study start (actual)2020-08-31Date precision: day

Registry last updated2023-02-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV Infectionsunresolved

Dyslipidemiasunresolved

Interventions

Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein)DRUG

Saline SolutionDRUG

Sponsors & collaborators

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)lead sponsor

University of Maryland, Baltimorecollaborator

Mapped research locations

BaltimoreMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03960541 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.